The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Rocornal     N,N-diethyl-4-methyl- 1,5,7,9...

Synonyms: Avantrin, Trapymin, trapidil, Trapymine, Trapidilum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Trapymin


High impact information on Trapymin


Chemical compound and disease context of Trapymin


Biological context of Trapymin


Anatomical context of Trapymin


Associations of Trapymin with other chemical compounds

  • At the 4-week restudy, there was a significant preservation of luminal diameter in the trapidil group compared with the control group (1.27 +/- 0.20 vs. 0.94 +/- 0.48 mm, respectively; p less than 0.005) [7].
  • Intravenous administration of Trapidil, as well as nitroglycerin, produced transient decreases in total coronary resistance followed by sustained dilation of the large coronary artery [20].
  • This study was designed (i) to determine if local administration of trapidil (triazolopyrimidine) into a vessel wall reduces neointima formation, and (ii) to explore the mechanism involved in the subsequent reduction in cell proliferation [21].
  • In contrast, at high concentrations (3 X 10(-3) - 1 X 10(-2) M), trapidil markedly depressed or blocked the isoproterenol-induced slow action potentials [16].
  • At 5 X 10(-3) M, trapidil completely blocked the fast Na+ channels in hearts perfused with normal Tyrode solution, since this dose abolished the action potential when verapamil (2 X 10(-6) M) was present to eliminate the inward slow current [16].

Gene context of Trapymin


Analytical, diagnostic and therapeutic context of Trapymin

  • Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit [7].
  • CONCLUSIONS: Trapidil reduces restenosis after PTCA at the dosage of 100 mg TID and favorably influences the clinical outcome thereafter [6].
  • Intimal thickness was significantly less for the trapidil group than for the control group (0.33 +/- 0.15 vs. 0.44 +/- 0.15 mm, respectively; p = 0.01), as well as medial thickness (0.09 +/- 0.03 vs. 0.11 +/- 0.03 mm, respectively; p = 0.01) [7].
  • Patients received either trapidil 100 mg TID or aspirin at the same dosage at least 3 days before angioplasty and for 6 months thereafter [6].
  • RESULTS: Of 312 patients randomized at 21 centres in nine countries, 303 (148 trapidil, 155 placebo) underwent successful Wallstent implantation, and 139 patients (90%) in the placebo group and 130 (88%) in the trapidil group had repeat catheterization at 26+/-2 weeks [2].


  1. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment. Siegerstetter, V., Huber, M., Ochs, A., Blum, H.E., Rössle, M. Hepatology (1999) [Pubmed]
  2. The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. Serruys, P.W., Foley, D.P., Pieper, M., Kleijne, J.A., de Feyter, P.J. Eur. Heart J. (2001) [Pubmed]
  3. Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism. Lotinun, S., Sibonga, J.D., Turner, R.T. Endocrinology (2003) [Pubmed]
  4. Matrix metalloproteinase 2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. Nagashima, H., Aoka, Y., Sakomura, Y., Uto, K., Sakuta, A., Aomi, S., Kurosawa, H., Hagiwara, N., Kawana, M., Kasanuki, H. J. Vasc. Surg. (2004) [Pubmed]
  5. CD40-CD40 Ligand Mediates the Recruitment of Leukocytes and Platelets in the Inflamed Murine Colon. Vowinkel, T., Anthoni, C., Wood, K.C., Stokes, K.Y., Russell, J., Gray, L., Bharwani, S., Senninger, N., Alexander, J.S., Krieglstein, C.F., Grisham, M.B., Granger, D.N. Gastroenterology (2007) [Pubmed]
  6. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Maresta, A., Balducelli, M., Cantini, L., Casari, A., Chioin, R., Fabbri, M., Fontanelli, A., Monici Preti, P.A., Repetto, S., De Servi, S. Circulation (1994) [Pubmed]
  7. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Liu, M.W., Roubin, G.S., Robinson, K.A., Black, A.J., Hearn, J.A., Siegel, R.J., King, S.B. Circulation (1990) [Pubmed]
  8. Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Takikita-Suzuki, M., Haneda, M., Sasahara, M., Owada, M.K., Nakagawa, T., Isono, M., Takikita, S., Koya, D., Ogasawara, K., Kikkawa, R. Am. J. Pathol. (2003) [Pubmed]
  9. Prevention of cerebral ischemic symptoms in cerebral vasospasm with trapidil, an antagonist and selective synthesis inhibitor of thromboxane A2. Suzuki, S., Sobata, E., Iwabuchi, T. Neurosurgery (1981) [Pubmed]
  10. Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro. Kuratsu, J., Ushio, Y. J. Neurosurg. (1990) [Pubmed]
  11. Pharmacological management of an impending placental insufficiency. Köpernick, H., Mest, H.J., Schwarz, B. Prostaglandins Leukot. Essent. Fatty Acids (1988) [Pubmed]
  12. Effects of trapidil and nitroglycerin on coronary circulation in conscious dogs. Noguchi, K., Tomoike, H., Kawachi, Y., Nabeyama, S., Shimokawa, H., Maruoka, Y., Nakamura, M. Arzneimittel-Forschung. (1984) [Pubmed]
  13. Effect of trapidil on prostacyclin generation of arterial wall. Kawamura, T., Kitani, T., Okajima, Y., Okuda, S., Urano, S., Watada, M., Nakagawa, M., Ijichi, H. Prostaglandins and medicine. (1980) [Pubmed]
  14. Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A. Bönisch, D., Weber, A.A., Wittpoth, M., Osinski, M., Schrör, K. Mol. Pharmacol. (1998) [Pubmed]
  15. Trapidil inhibits human mesangial cell proliferation: effect on PDGF beta-receptor binding and expression. Gesualdo, L., Di Paolo, S., Ranieri, E., Schena, F.P. Kidney Int. (1994) [Pubmed]
  16. Concentration-dependent effect of trapidil on slow action potentials in cardiac muscle. Azuma, J., Harada, H., Sawamura, A., Hasegawa, H., Kishimoto, S., Sperelakis, N. J. Mol. Cell. Cardiol. (1983) [Pubmed]
  17. Pharmacokinetics of trapidil in patients with chronic liver disease. Berndt, A., Looby, M., Pönicke, K., Zipprich, B., Weiss, M. Journal of clinical pharmacology. (1996) [Pubmed]
  18. Trapidil inhibits platelet-derived growth factor-stimulated mitogen-activated protein kinase cascade. Hoshiya, M., Awazu, M. Hypertension (1998) [Pubmed]
  19. Trapidil inhibits monocyte chemoattractant protein-1 and macrophage accumulation after balloon arterial injury in rabbits. Poon, M., Cohen, J., Siddiqui, Z., Fallon, J.T., Taubman, M.B. Lab. Invest. (1999) [Pubmed]
  20. Difference in site and time course of coronary dilating effects of trapidil, nitroglycerin and dipyridamole in anesthetized dogs. Noguchi, K., Tomoike, H., Ootsubo, H., Sakai, K., Nakamura, M. J. Pharmacol. Exp. Ther. (1981) [Pubmed]
  21. Effects of local delivery of trapidil on neointima formation in a rabbit angioplasty model. Zacharowski, K., Schneidmüller, D., Ibe, W., Grosser, T., Buerke, M., Meyer, J., Darius, H. Br. J. Pharmacol. (2000) [Pubmed]
  22. Effect of trapidil on effector functions of monocytes related to atherosclerotic plaque. Kato, Y., Tsuda, T., Hosaka, Y., Takahashi, T., Shirakawa, K., Furusako, S., Mizuguchi, K., Mochizuki, H. Eur. J. Pharmacol. (2001) [Pubmed]
  23. Trapidil effects on intimal thickening and mRNA levels for platelet-derived growth factor A in human saphenous vein smooth muscle cells. Yamaguchi, M., Kumada, K. Am. J. Surg. (1998) [Pubmed]
  24. Trapidil inhibits monocyte CD40 expression by preventing IFN-gamma-induced STAT1 S727 phosphorylation. Zhou, L., Schandené, L., Mordvinov, V.A., Chatelain, P., Pradier, O., Goldman, M., Stordeur, P. Int. Immunopharmacol. (2004) [Pubmed]
WikiGenes - Universities